复发难治多发性骨髓瘤深度缓解翻倍！CELMoD药物iberdomide Ⅲ期研究主要终点数据重磅公布
在 2026 年国际骨髓瘤研讨会（ IMS 2026 ）上公布的研究结果显示，相比达雷妥尤单抗联合硼替佐米及地塞米松， iberdomide 联合达雷妥尤单抗和地塞米松使微小残留病（ MRD ）阴性完全缓解率翻倍（ 41.1% vs. 20.7% ） 数据进一步证实了基于 iberdomide 的三药联合方案是复发或难治性多发性骨髓瘤患者（早至首次复发）有效、给药便捷的治疗选择 研究结果已同步发表于《柳叶刀 • 肿瘤学》 上海 2026年9月29日 /美通社/ -- 近日，百时美施贵宝首次公布了关键III期EXCALIBER-RRMM研究（NCT04975997）预设分析的结果。该研究旨在评估iberdomide联合达雷妥尤单抗和地…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- RevitaLash® Cosmetics 推出 RevitaLash 肽复合物+ 定时释放睫毛护发素，这是一款不含前列腺素类似物制成的革命性睫毛精华
- 看鉴她力量：苏菲聚焦经期血块痛点，探索女性关怀新表达
- 东成连续三年入选《亚洲品牌500强》
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →